Akero Therapeutics (AKRO)
(Delayed Data from NSDQ)
$28.05 USD
-0.32 (-1.13%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $28.07 +0.02 (0.07%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
AKRO 28.05 -0.32(-1.13%)
Will AKRO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for AKRO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AKRO
Amicus (FOLD) Up as Q2 Earnings & Sales Top, '24 View Updated
Xenon (XENE) Q2 Earnings Miss, Pipeline in Focus, Stock Down
AKRO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Intra-Cellular (ITCI) Q2 Loss Narrower Than Expected, Sales Beat
Viatris (VTRS) Q2 Earnings Outpace Estimates, Sales Miss
Catalyst (CPRX) Rises as Q2 Earnings & Revenues Beat Estimates
Other News for AKRO
Akero Therapeutics: Good Candidate For The MASH Basket
Buy Rating Affirmed for Akero Therapeutics Amid Promising Phase 3 Drug Trial for MASH Treatment
Wellington Management Group LLP's Strategic Acquisition in Akero Therapeutics Inc
Tracking Baker Brothers Portfolio - Q2 2024 Update
Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH